drugset
Drugs / Recombinant human growth hormone (r-hGH)
last change Jan 2017 re-read 3 minutes ago

Recombinant human growth hormone (r-hGH)

Protein / enzyme biologic

Developed for
hypochondroplasia
Investigated by
Merck KGaA, Darmstadt, Germany · Merck Serono S.A.S, France

Trials 1

today NCT01111019 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01111019 Mar 2006 → Jan 2017 hypochondroplasia Merck KGaA, Darmstadt, Germany Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant human growth hormone (r-hGH) ClinicalTrials.gov intervention name — accepted as the source's own label NCT01111019 ↗
Modality Protein / enzyme biologic “recombinant human growth hormone (r-hGH)” NCT01111019 ↗
Route Subcutaneous “Subjects will receive a single subcutaneous injection” NCT01111019 ↗